Supplementary Material

Search Strategies

All results were imported to Covidence. Duplicates were removed by Covidence.

**PubMed**


AND

("pancreatitis"[MeSH Terms] OR "Pancreatitis, Acute Hemorrhagic"[Mesh] OR "Pancreatitis, Acute Necrotizing"[Mesh] pancreatitis OR interstitial pancreatitis OR acute pancreatitis OR pancreatic injur* OR pancreas OR pancreatic damage OR amylase OR lipase OR hyperamylasemia OR hyperlipasemia)

NOT

(animals[mesh] NOT humans[mesh])

**Embase**

('coronavirus disease 2019'/exp OR 'Severe acute respiratory syndrome coronavirus 2'/exp OR covid OR 'covid 19' OR coronavirus OR 'sars-cov-2' OR '2019 ncov' OR '2019 novel coronavirus' OR 'severe acute respiratory syndrome coronavirus 2')

AND

('pancreatitis'/exp OR 'acute pancreatitis'/exp OR pancreatitis OR 'pancreas injury'/exp OR 'interstitial pancreatitis' OR 'acute pancreatitis' OR 'pancreatic injur*' OR pancreas OR 'pancreatic damage' OR amylase OR lipase OR hyperamylasemia OR hyperlipasemia)

NOT ((animal/exp OR nonhuman) NOT human/exp)

AND [embase]/lim NOT ([embase]/lim AND [medline]/lim)

**Scopus**

TITLE-ABS-KEY ("coronavirus disease 2019" OR "severe acute respiratory syndrome coronavirus 2" OR “covid 19” OR covid OR coronavirus OR “sars-cov-2” OR “2019 ncov” OR “2019 novel coronavirus”)

AND
TITLE-ABS-KEY (pancreatitis OR “acute pancreatitis” OR “pancreas injur*” OR “interstitial pancreatitis” OR “pancreas” OR “pancreatic damage” OR amylase OR lipase OR hyperamylasemia OR hyperlipasemia)

Cochrane Library

("coronavirus disease 2019" OR "severe acute respiratory syndrome coronavirus 2" OR “covid 19” OR covid OR coronavirus OR “sar-cov-2” OR “2019 ncov” OR “2019 novel coronavirus”)
AND
(pancreatitis OR “acute pancreatitis” OR “pancreas injur*” OR “interstitial pancreatitis” OR “pancreas” OR “pancreatic damage” OR amylase OR lipase OR hyperamylasemia OR hyperlipasemia)
In All Text
<table>
<thead>
<tr>
<th>First author</th>
<th>Country</th>
<th>Study design</th>
<th>Centers</th>
<th>Study period</th>
<th>Sample size</th>
<th>No. of AP with COVID-19</th>
<th>Quality assessment†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Akarsu</td>
<td>Turkey</td>
<td>Prospective cohort study</td>
<td>Single center</td>
<td>2020.3.25-2020.4.2</td>
<td>5</td>
<td>316 with COVID-19</td>
<td>40</td>
</tr>
<tr>
<td>Bulthuis</td>
<td>Netherlands</td>
<td>Prospective cohort study</td>
<td>Bi-center</td>
<td>2020.3.4-2020.5.26</td>
<td>432</td>
<td>8</td>
<td>8</td>
</tr>
<tr>
<td>Dirweesh</td>
<td>USA</td>
<td>Retrospective cohort study</td>
<td>Multi-center</td>
<td>2020.3.1-2020.6.30</td>
<td>339</td>
<td>14</td>
<td>14</td>
</tr>
<tr>
<td>Inamdar</td>
<td>USA</td>
<td>Retrospective cohort study</td>
<td>Multi-center</td>
<td>2020.3.1-2020.6.1</td>
<td>189</td>
<td>32</td>
<td>32</td>
</tr>
<tr>
<td>Kumar</td>
<td>USA</td>
<td>Retrospective cohort study</td>
<td>Multi-center</td>
<td>2020.2.1-2020.6.30</td>
<td>985</td>
<td>17</td>
<td>17</td>
</tr>
<tr>
<td>Miró</td>
<td>Spain</td>
<td>Retrospective case control study</td>
<td>Multi-center</td>
<td>2020.3.1-2020.4.30</td>
<td>74814</td>
<td>54</td>
<td>54</td>
</tr>
<tr>
<td>Pandanaboyana</td>
<td>Multiple</td>
<td>Prospective cohort study</td>
<td>Multi-center</td>
<td>2020.3.1-2020.7.23</td>
<td>1777</td>
<td>149</td>
<td>149</td>
</tr>
<tr>
<td>Szatmary</td>
<td>UK</td>
<td>Case series</td>
<td>Single center</td>
<td>2020.3.14-2020.4.30</td>
<td>35</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Vatansiev</td>
<td>Turkey</td>
<td>Retrospective cohort study</td>
<td>Single center</td>
<td>2020.4-2020.6</td>
<td>150</td>
<td>29</td>
<td>29</td>
</tr>
<tr>
<td>Ding</td>
<td>China</td>
<td>Retrospective cohort study</td>
<td>Single center</td>
<td>2020.1-2020.3</td>
<td>55</td>
<td>3</td>
<td>3</td>
</tr>
<tr>
<td>Karaali</td>
<td>Turkey</td>
<td>Retrospective observational study</td>
<td>Single center</td>
<td>2020.3-2020.12</td>
<td>189</td>
<td>83</td>
<td>83</td>
</tr>
</tbody>
</table>

† According to the modified Newcastle-Ottawa Scale.
* Including patients with COVID-19 diagnosed exclusively based on clinical criteria.
Modified Newcastle-Ottawa Quality Assessment Scale (Cohort studies)

Selection
1) Representativeness of the exposed cohort
   a) truly representative of the average population with acute pancreatitis / COVID-19 in the community
   b) somewhat representative of the average population with acute pancreatitis / COVID-19 in the community
   c) selected group of users eg nurses, volunteers
   d) no description of the derivation of the cohort
2) Selection of the non exposed cohort
   a) drawn from the same community as the exposed cohort
   b) drawn from a different source
   c) no description of the derivation of the non exposed cohort
3) Ascertainment of exposure
   a) clearly record using the standardized diagnostic criteria
   b) record without details on the diagnostic criteria
   c) written self report
   d) no description
4) Demonstration that outcome of interest was not present at start of study
   a) yes
   b) no

Comparability
1) Comparability of cohorts on the basis of the design or analysis
   a) study controls for age
   b) study controls for any additional factor

Outcome
1) Assessment of outcome
   a) independent blind assessment
   b) record linkage
   c) self / family report
   d) no description
2) Was follow-up long enough for outcomes to occur
   a) yes (select an adequate follow up period for outcome of interest)
   b) no
3) Adequacy of follow up of cohorts
   a) complete follow up - all subjects accounted for
   b) subjects lost to follow up unlikely to introduce bias
   c) subjects lost to follow up may introduce bias
   d) no statement
**Supplementary Figures**

**Supplementary Figure 1.** Flowchart of study selection.

![Flowchart of study selection](image1)

**Supplementary Figure 2.** Funnel plot of the arcsine transformed mortality.

The visual inspection of the funnel plot indicated relative symmetry.

![Funnel plot of the arcsine transformed mortality](image2)